苏沃雷生降低老年住院患者谵妄的随机临床试验
这项双盲、安慰剂对照的3期随机临床试验在日本50家医院开展,纳入65~90岁、因急性疾病或择期手术住院且谵妄高风险(轻度认知障碍或轻度痴呆、既往住院有谵妄史或两者兼有)的日本成人,1:1随机接受苏沃雷生15 mg或安慰剂睡前服用、住院期间最多7天。主要终点为住院期间依据《精神障碍诊断与统计手册》第五版标准诊断的谵妄。结果显示苏沃雷生组17例(16.8%)出现谵妄,安慰剂组27例(26.5%),差值-8.7%(95%CI -20.1%~2.6%),P=0.13,未达统计学显著;两组不良事件相似。作者认为需要进一步研究确定苏沃雷生是否可能有助于减少该人群的谵妄,尤其是伴有高活动成分的谵妄。
要点
- 高谵妄风险老年住院患者睡前服用苏沃雷生15 mg、最多7天,谵妄发生率16.8%(17/101)vs 安慰剂26.5%(27/102),差值-8.7%(95%CI -20.1%~2.6%),P=0.13,未达统计学显著。
- 两组不良事件相似,原文未报告具体不良事件类型与例数。
- 研究人群为65~90岁、因急性疾病或择期手术住院,且存在轻度认知障碍或轻度痴呆、既往住院谵妄史或两者兼有的高谵妄风险者。
- 作者认为需要进一步研究确定苏沃雷生是否可能有助于减少该人群的谵妄,尤其是伴有高活动成分的谵妄。
适用人群与场景
- 日本65~90岁成人,因急性疾病或择期手术住院,且为谵妄高风险:轻度认知障碍或轻度痴呆、既往住院时有谵妄史、或两者兼有。
诊断标准与关键阈值
- 谵妄诊断依据《精神障碍诊断与统计手册》第五版(DSM-5)标准,于住院期间评估。
处置流程与药物剂量
- 苏沃雷生15 mg或安慰剂,睡前服用,住院期间最多7天。
研究设计与关键结果
- 双盲、安慰剂对照、3期随机临床试验,日本50家医院,2020年10月22日至2022年12月23日纳入203例:苏沃雷生组101例(平均[SD]年龄81.5[4.5]岁;男52例[51.5%]、女49例[48.5%]),安慰剂组102例(平均[SD]年龄82.0[4.9]岁;男45例[44.1%]、女57例[55.9%])。
- 主要终点:苏沃雷生组谵妄17例(16.8%)vs 安慰剂组27例(26.5%),差值-8.7%(95%CI -20.1%~2.6%),P=0.13。
- 不良事件两组相似。
证据类型、等级与局限
- 证据类型:双盲、安慰剂对照、3期随机临床试验。
- 局限:作者指出需要进一步研究确定苏沃雷生是否可能有助于减少该人群的谵妄,尤其是伴有高活动成分的谵妄。
对床旁实践的改变
- 作者认为,需要进一步研究确定苏沃雷生是否可能有助于减少高谵妄风险老年住院患者的谵妄,尤其是伴有高活动成分的谵妄;本研究主要终点未达统计学显著,未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Delirium is common among older hospitalized adults. In addition to presenting immediate management issues, delirium can increase the long-term risk of dementia, institutionalization, and mortality. Delirium is associated with disrupted sleep, and prior studies suggest that some specific sleep-promoting agents may reduce delirium.
OBJECTIVE: To evaluate the orexin receptor antagonist suvorexant for reducing delirium in older adults at high risk for delirium after hospitalization.
DESIGN, SETTING, AND PARTICIPANTS: This double-blind, placebo-controlled, phase 3 randomized clinical trial was conducted at 50 hospitals in Japan between October 22, 2020, and December 23, 2022. The study population included Japanese adults aged 65 to 90 years who were at high risk for delirium (mild cognitive impairment or mild dementia, history of delirium at prior hospitalization, or both) and had been hospitalized for acute disease or elective surgery. Data analysis was performed between January 23 and March 13, 2023.
INTERVENTION: Participants were randomized 1:1 to suvorexant (15 mg) or placebo taken at bedtime for up to 7 days while in the hospital.
MAIN OUTCOMES AND MEASURES: Delirium, the primary end point, was diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria while participants were hospitalized. The treatment difference in the proportion of participants with delirium was analyzed.
RESULTS: This study included 203 participants: 101 were treated with suvorexant (mean [SD] age, 81.5 [4.5]; years; 52 men [51.5%] and 49 women [48.5%]) and 102 received placebo (mean [SD] age, 82.0 [4.9] years; 45 men [44.1%] and 57 women [55.9%]). There were 17 participants with delirium (16.8%) in the suvorexant group compared with 27 (26.5%) in the placebo group (difference, -8.7% [95% CI, -20.1% to 2.6%]; P = .13). Adverse events were similar between the 2 groups.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of suvorexant in older adults at high risk for delirium after hospitalization, fewer participants taking suvorexant had delirium compared with placebo, but the difference was not statistically significant. Further studies are needed to determine whether suvorexant may be useful for reducing delirium, particularly delirium with a hyperactive component, in this population.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04571944.
参考来源
- Hatta K, Kishi Y, Wada K, et al. Suvorexant for Reduction of Delirium in Older Adults After Hospitalization: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39150711. doi:10.1001/jamanetworkopen.2024.27691
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。